CagriSema para la pérdida de peso en la obesidad

Cagrilintide

Semaglutide

Placebo cagrilintide

Placebo semaglutide

Relative change in body weight

Number of participants who achieve greater than or equal to (>=) 20 percent body weight reduction

Number of participants who achieve >= 25 percent body weight reduction

Number of participants who achieve >= 30 percent body weight reduction

Change in waist circumference

Change in waist to height ratio

Change in Systolic Blood Pressure (SBP)

Ratio to Baseline in Lipids: Total Cholesterol

Ratio to Baseline in Lipids: High Density Lipoprotein (HDL) Cholesterol

Ratio to Baseline in Lipids: Low Density Lipoprotein (LDL) Cholesterol

Ratio to Baseline in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol

Ratio to Baseline in Lipids: Triglycerides

Ratio to Baseline in Lipids: Free fatty acids

Ratio to Baseline in Lipids: Non-HDL cholesterol

Change in Body Mass Index (BMI)

Number of participants who achieve BMI less than 30 kg/m^2

Change in Glycated Haemoglobin (HbA1c) (percentage points)

Change in HbA1c (millimoles per mole [mmol/mol])

Change in Fasting Plasma Glucose (FPG) (millimoles per liter [mmol/L])

Change in FPG (milligrams per deciliter [mg/dL])

Number of participants who achieve HbA1c less than (<) 5.7 percent and FPG < 100 mg/dL with prediabetes at baseline

Number of participants who achieve HbA1c >= 6.5 percent or FPG >= 126 mg/dL with prediabetes at baseline

Time to HbA1c < 5.7 percent and FPG < 100 mg/dL with prediabetes at baseline

Time to HbA1c >= 6.5 percent or FPG >= 126 mg/dL with prediabetes at baseline

Number of participants who develop HbA1c >= 5.7 percent or FPG greater than (>) 100 mg/dL with normoglycemia at baseline

Number of participants who develop type 2 diabetes (T2D) as per American Diabetes Association (ADA) guideline

Time to T2D diagnosis as per ADA guideline

Change in American College of Cardiology/American Heart Association (ACC/AHA) 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score

Number of participants who improve in >= 1 pre-existing cardiometabolic obesity related com-plication (ORC) (hypertension, prediabetes, or dyslipidaemia)

Ratio to baseline in C-reactive protein (CRP)

Change in total fat mass by dual energy X-ray absorption (DXA) absolute to total body mass (kilogram [kg])

Change in total fat mass by DXA relative to total body mass (kg)

Change in total fat mass by DXA absolute to total body mass (percentage points)

Change in total fat mass by DXA relative to total body mass (percentage points)

Change in visceral fat mass by DXA, relative to baseline in visceral fat mass region (percentage)

Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (percentage)

Change in visceral fat mass by DXA, relative to baseline in visceral fat mass region (percentage points)

Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (percentage points)

Change in lean body mass by DXA absolute to total body mass (kg)

Change in lean body mass by DXA relative to total body mass (kg)

Change in lean body mass by DXA absolute to total body mass (percentage points)

Change in lean body mass by DXA relative to total body mass (percentage points)

Change in Short Form (SF)-36 Physical functioning score

Change in Impact of Weight on Quality of Life-Lite for clinical trials (IWQOL-Lite-CT): Physical Function Score

Change in IWQOL-Lite-CT: Physical Score

Change in IWQOL-Lite-CT: Psychosocial score

Change in IWQOL-Lite-CT: Total score

Change in Impact of Weight on Daily Activities Questionnaire (IWDAQ) Composite score

Change in Control of Eating questionnaire (CoEQ): Craving Control score

Change in CoEQ: Positive Mood score

Change in CoEQ: Craving for Sweets score

Change in CoEQ: Craving for Savoury score

Change in CoEQ: Hunger score

Change in CoEQ: Satiety score

CagriSema s.c. 2.4 mg/2.4 mg versus placebo: Number of Treatment Emergent Adverse Events (TEAEs)

CagriSema s.c. 2.4 mg/2.4 mg versus placebo: Number of Treatment Emergent Serious Adverse Events (TESAEs)

CagriSema s.c. 2.4 mg/2.4 mg versus CagriSema s.c. dose tapering algorithm: Number of TEAEs

CagriSema s.c. 2.4 mg/2.4 mg versus CagriSema s.c. dose tapering algorithm: Number of TESAEs

CagriSema 2.4 mg/2.4 mg: Number of TEAEs

CagriSema 2.4 mg/2.4 mg: Number of TESAEs